

Date: 14.02.2023

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Sub: - Unaudited Financial Result of the Company under Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the Quarter and nine months ended on 31st December, 2022

Company Scrip Code: 532167

Dear Sir(s),

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please find enclosed herewith:

Unaudited Financial Results of the Company along with Limited Review Report for the Quarter and nine months ended on 31st December, 2022.

The aforesaid result has been approved by the Board of Directors in their meeting held on 14th February, 2023.

This is for your information and record.

Thanking You,

Yours faithfully,
For **Omkar Pharmachem Limited**



Bhawani Shankar Goyal
Managing Director
DIN: 03255804

Add: House No. - 155/2, First Floor, Gali No - 2
Near Gurudwara, Govindpuri, Kalkaji- 110019
Delhi

Encl: a/a

Omkar Pharmachem Ltd.

Statement of Standalone Unaudited Financial Results for the Quarter & Nine Months ended on 31st December, 2022

(Rs. in lakhs except per share data)

| Sr. | Particulars | Quarter Ended on | | | Nine Months Ended on | | Year Ended On |
|-----|--|------------------|---------------|---------------|----------------------|---------------|---------------|
| | | 31-12-2022 | 30-09-2022 | 31-12-2021 | 31-12-2022 | 31-12-2021 | 31-03-2022 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| | Part-I | | | | | | |
| 1 | Income from operations | | | | | | |
| | a) Net Sales/ Income from Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | b) Other Operating Income | 13.50 | 13.50 | 13.50 | 40.50 | 40.50 | 54.00 |
| | Total | 13.50 | 13.50 | 13.50 | 40.50 | 40.50 | 54.00 |
| 2 | Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 3 | Net Total Income | 13.50 | 13.50 | 13.50 | 40.50 | 40.50 | 54.00 |
| 4 | Expenses | | | | | | |
| | a) Cost of material consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | b) Purchase of Stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | c) Changes in Inventories of Finished Goods, WIP and Stock-in trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | d) Employee benefits expenses | 3.32 | 4.37 | 4.38 | 12.06 | 13.11 | 17.49 |
| | e) Finance Costs | 0.00 | 0.00 | 0.00 | 0.00 | 2.28 | 5.58 |
| | f) Depreciation and Amortization Expenses | 0.07 | 0.07 | 0.07 | 0.20 | 0.10 | 0.19 |
| | g) Other Expenses | 1.74 | 1.38 | 0.93 | 7.62 | 6.79 | 9.69 |
| | Total Expenses | 5.13 | 5.82 | 5.38 | 19.88 | 22.28 | 32.95 |
| 5 | Profit(Loss) from operations before Exceptional Items & Taxes (3-4) | 8.37 | 7.68 | 8.12 | 20.62 | 18.22 | 21.05 |
| 6 | Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 7 | Profit(Loss) before Tax (5+6) | 8.37 | 7.68 | 8.12 | 20.62 | 18.22 | 21.05 |
| 8 | Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.74 |
| 9 | Profit(Loss) for the period (7-8) | 8.37 | 7.68 | 8.12 | 20.62 | 18.22 | 18.31 |
| 10 | Other Comprehensive Income (Expense) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 11 | Total Comprehensive Income for the period (9+10) | 8.37 | 7.68 | 8.12 | 20.62 | 18.22 | 18.31 |
| 12 | Paid up Equity Share Capital (Face Value Rs. 10/-each) | 1008.37 | 1008.37 | 1008.37 | 1008.37 | 1008.37 | 1008.37 |
| 13 | Other Equity | - | - | - | - | - | (123.79) |
| 14 | Earning Per Share(before & after extraordinary items)(of Rs. 10 each)(not annualised) Basic and diluted Rs. | 0.0830 | 0.0762 | 0.0805 | 0.2045 | 0.1807 | 0.1816 |

Notes:

- The above results have been reviewed by the audit committee & approved by the Board of Directors at their respective meetings held on 14th February 2023.
- Corresponding previous period figures are regrouped/rearranged wherever necessary, to make them comparable.
- The IND-AS regarding segment reporting is not applicable to the company as there is no segment.
- The Financial Results for the Quarter and Nine months ended on December 31, 2022 has been prepared in accordance with the Ind-As specified under Section 133 of the companies Act, 2013 and Rules made there under.

By order of the Board



(Bhawani Shankar Goyal)

Managing Director

DIN: 03255804

House No.155/2, First Floor, Gali No - 2, Near Gurudwara, Govindpuri, Kalkaji, Delhi-110019

Date : 14-02-2023
Place: Ahmedabad



Limited Review Report to the Board of Directors of **Omkar Pharmachem Limited**
for quarter and nine months ended on 31st December, 2022

We have reviewed the accompanying statement of unaudited financial results of **Omkar Pharmachem Limited** for the quarter and nine months ended on 31st December, 2022. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and; thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure



Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rajesh J. Shah & Associates
Chartered Accountants
FRN 108407W



CA Jimit R Shah
(Partner)

M. No. - 163920

UDIN: 23163920BGUXWJ4704

Place: Ahmedabad
Date: 14/02/2023

